natgillin/translations-raw huggingface dataset:
What is the risk associated with Ganfort? 
Kakšna tveganja so povezana z zdravilom Ganfort?
The most common side effect (seen in more than 1 patient in 10) is conjunctival hyperaemia (increased blood supply to the eye, leading to redness of the eye). 
Najpogostejši neželeni učinek (opažen pri več kot 1 bolniku od 10) je konjunktivna hiperemija (zvišan dotok krvi v oko, kar povzroči njegovo pordelost).
‘Ocular hypertension' is when the pressure in the eye is higher than normal. 
Očesna hipertenzija je stanje, pri katerem je tlak v očesu višji od običajnega.
It is used in adults with ‘open angle glaucoma' or ocular hypertension who do not respond sufficiently to eye drops containing beta-blockers or prostaglandin analogues (other medicines used for these conditions). 
Uporablja se pri odraslih z glavkomom odprtega zakotja ali očesno hipertenzijo, ki se ne odzivajo dovolj na kapljice za oči, ki vsebujejo antagoniste adrenergičnih receptorjev beta ali analoge prostaglandina (drugi vrsti zdravil, ki se uporabljajo za zdravljenje teh bolezni).
Ganfort must not be used in patients who have asthma or severe lung disease, or in patients with some heart conditions. 
Zdravilo Ganfort se ne sme uporabljati pri bolnikih z astmo, hudim pljučnim obolenjem ali nekaterimi srčnimi obolenji.
For the full list of all side effects reported with Ganfort, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Ganfort, glejte navodilo za uporabo.
Raised pressure in the eye causes damage to the retina (the light sensitive membrane at the back of the eye) and to the optic nerve that sends signals from the eye to the brain. 
Zvišan očesni tlak poškoduje mrežnico (membrano na zadnji strani zrkla, ki je občutljiva za svetlobo) in vidni živec, ki pošilja signale iz očesa v možgane.
Overall, the studies showed that Ganfort is effective in lowering eye pressure. 
Na splošno so študije pokazale, da zdravilo Ganfort učinkovito znižuje očesni tlak.
Ganfort contains two active substances, bimatoprost and timolol, which lower the pressure in the eye in different ways. 
Zdravilo Ganfort vsebuje dve zdravilni učinkovini: bimatoprost in timolol, ki na različne načine znižujeta tlak v očesu.
Why has Ganfort been approved? 
Zakaj je bilo zdravilo Ganfort odobreno?
Ganfort is used to reduce the pressure inside the eye. 
Zdravilo Ganfort se uporablja za zniževanje tlaka v očesu.
Ganfort was more effective than timolol on its own and was as effective as bimatoprost. 
Zdravilo Ganfort je bilo učinkovitejše od samostojne uporabe timolola in enako učinkovito kot bimatoprost.
In addition, Ganfort was shown to be as effective as bimatoprost and timolol given at the same time. 
Dokazano je bilo tudi, da je zdravilo Ganfort enako učinkovito kot sočasna uporaba bimatoprosta in timolola.
By lowering the pressure, Ganfort reduces the risk of damage. 
Zdravilo Ganfort z zniževanjem tlaka zmanjša nevarnost poškodb.
Bimatoprost is a prostaglandin analogue, (a copy of the natural substance prostaglandin) that works by increasing the drainage of fluid out of the eye. Bimatoprost on its own has already been approved in the European Union under the name Lumigan. 
Bimatoprost je analog prostaglandina (kopija naravnega prostaglandina), ki deluje tako, da poveča odtok tekočine iz očesa.
How has Ganfort been studied? 
Kako je bilo zdravilo Ganfort raziskano?
What is Ganfort? 
Kaj je zdravilo Ganfort?
How is Ganfort used? 
Kako se zdravilo Ganfort uporablja?
Timolol is a beta-blocker that works by reducing the production of fluid within the eye. Timolol has been commonly used to treat glaucoma since the 1970s. 
Timolol je v splošni uporabi za zdravljenje glavkomov že od sedemdesetih let prejšnjega stoletja dalje.
What is Ganfort used for? 
Za kaj se zdravilo Ganfort uporablja?
How does Ganfort work? 
Kako zdravilo Ganfort deluje?
The Member States should agree the local implementation of the patient card system. 
Države članice se morajo dogovoriti o lokalnem izvajanju sistema kartic bolnika.
• The feasibility of collecting detailed data relating to the indication in order to monitor closely the offlabel use within the national territory. 
• o možnosti zbiranja podrobnih podatkov v zvezi z indikacijo, da bi skrbno nadzorovali nenamensko uporabo znotraj nacionalega teritorija;
The Member States shall ensure that the MAH implements a pregnancy prevention programme (PPP) within their territory. 
Države članice morajo zagotoviti, da imetnik dovoljenja za promet z zdravili izvaja program za preprečevanje nosečnosti (PPN) znotraj svojega teritorija.
Patient Card 
Kartica bolnika
• The need to avoid foetal exposure due to teratogenicity of lenalidomide in animals and the expected teratogenic effect of lenalidomide in humans including a summary of the results of study CC-5013TOX-004 
• potrebo po izogibanju fetalni izpostavljenosti zaradi teratogenosti lenalidomida pri živalih in pričakovanega teratogenega učinka lenalidomida na človeka, vključno s povzetkom rezultatov študije CC-5013-TOX004;
• CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
• POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH MORAJO IZVAJATI DRŽAVE ČLANICE
• That lenalidomide is teratogenic in animals and is expected to be teratogenic in humans. 
• opozorilo, da je lenalidomid teratogen pri živalih in se pričakuje teratogenost pri človeku;
The Member States must ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented: 
Države članice morajo zagotoviti, da se izvajajo vsi spodaj opisani pogoji ali omejitve v zvezi z varno in učinkovito uporabo zdravila:
• That Revlimid may cause neutropenia and thrombocytopenia and the need for regular blood tests 
• da zdravilo Revlimid lahko povzroča nevtropenijo in trombocitopenijo; potrebne so redne krvne preiskave;
• The set-up of national measures to assess the effectiveness of and compliance with the PPP 
• o vzpostavitvi nacionalnih ukrepov za določanje učinkovitosti in soglasje s PPN-jem.
The Educational brochures for patients should be of 3 types: 
Izobraževalne brošure za bolnike naj bodo treh vrst:
The Member States should agree the final text of the Direct Healthcare Professional Communication and the physician information pack contents with the MAH and ensure that the materials contain the key elements as described below. 
Države članice se morajo dogovoriti z imetnikom dovoljenja za promet z zdravili o končnem besedilu Neposrednega obvestila zdravstvenim delavcem in vsebinah paketa s podatki za zdravnike in zagotoviti, da gradiva vsebujejo ključne elemente, kot so opisane spodaj.
• Description of the patient card and its necessity 
• opis kartice bolnika in razlago, zakaj je nujna;
• That the patient should not give Revlimid to any other person 
• opozorilo, da bolnik ne sme dajati zdravila Revlimid nobeni drugi osebi;
• Description of the PPP 
• opis PPN-ja;
Details of the PPP should be agreed with the National Competent Authorities in each Member State and put in place prior to the marketing of the product. 
Podrobnosti PPN-ja bodo dogovorjene s pristojnimi nacionalnimi organi in pripravljene pred trženjem zdravila.
• National specific requirements agreed with the National Competent Authority regarding: o Distribution of the product o To ensure that all appropriate measures have been performed prior to Revlimid being dispensed 
• za državo značilnih zahtev, s soglasjem pristojnega nacionalnega organa, glede: o distribucije zdravila, o zagotovitve izvajanja vseh ustreznih ukrepov pred izdajanjem zdravila Revlimid.
• Prior to launch, all doctors who intend to prescribe Revlimid and all pharmacists who may dispense Revlimid receive a Direct Healthcare Professional Communication as described below. 
• pred lansiranjem zdravila na trg morajo vsi zdravniki, ki nameravajo predpisovati zdravilo Revlimid, in vsi farmacevti, ki bodo izdajali zdravilo Revlimid, prejeti Neposredno obvestilo zdravstvenim delavcem, kot je opisano spodaj;
The Member States shall agree the details of a controlled distribution system with the MAH according to national regulations and healthcare system and must implement such programme nationally to ensure that: 
Države članice se morajo o podrobnostih sistema za nadzorovano distribucijo dogovoriti z imetnikom dovoljenja za promet z zdravili in izvajati ta program na državni ravni, da tako zagotovi naslednje:
• Prior to prescribing (where appropriate, and in agreement with the National Competent Authority, dispensing) all healthcare professionals who intend to prescribe (and dispense) Revlimid are provided with a physician information pack containing the following: o Educational Health Care Professional's kit o Educational brochures for Patients o Patient cards o Summary of Product Characteristics (SmPC) and Package Leaflet and Labelling. 
• pred predpisovanjem (kjer je ustrezno, in v skladu s pristojnimi nacionalnimi organi, pred izdajanjem) bodo vsi zdravstveni delavci, ki nameravajo predpisovati (in izdajati) zdravilo Revlimid, prejeli paket s podatki za zdravnike, ki vsebuje naslednje: o izobraževalni paket za zdravstvene delavce, o izobraževalne brošure za bolnike, o kartice bolnika, o povzetek glavnih značilnosti zdravila (SPC), navodilo za uporabo in označevanje.
• Check list for physicians ensuring that patients receive the appropriate counselling concerning the treatment, contraceptive methods and pregnancy prevention appropriate for their sex and childbearing status 
• kontrolni seznam za zdravnike, ki zagotavlja, da je bil bolnik deležen ustreznega svetovanja o zdravljenju, kontracepcijskih metodah in preprečevanju nosečnosti, ki ustreza spolu in statusu zmožnosti zanositve
The Member States should also agree with the MAH prior to the launch of the product: 
Države članice se morajo tudi dogovoriti z imetnikom dovoljenja za promet z zdravili pred lansiranjem zdravila na trg:
The patient card shall contain the following elements: 
Kartica bolnika mora vsebovati naslednje elemente:
• The need to use condoms if sexual partner is pregnant or a WCBP (even if man has had vasectomy) o During Revlimid treatment o For one week following final dose 
• potrebo po uporabi kondomov, če je spolna partnerica noseča ali ŽRD (tudi, če je moški imel vazektomijo): o med zdravljenjem z zdravilom Revlimid, o še en teden po zadnjem odmerku;
• Description of the PPP and categorisation of patients based on sex and childbearing potential o Algorithm for implementation of PPP o Definition of women of childbearing potential (WCBP) and actions the physician should take if unsure 
• opis PPN-ja in razvrstitev bolnikov po spolu in zmožnosti zanositve: o algoritem za izvajanje PPN-ja, o opredelitev žensk v rodni dobi (ŽRD), in ukrepov, ki jih morajo zdravniki izvajati, kadar niso prepričani;
• Safety advice relevant to all patients o Description and management of neutropenia and thrombocytopenia including incidence rates from clinical trials o Description and management of thromboembolic risk including incidence rates from clinical trials and post-marketing experience o Use in patients with hepatic and/or renal impairment o Disposal of unwanted medicine o Local country specific arrangements for a prescription for Revlimid to be dispensed o Description of risk of hypothyroidism o Explanation of unknown risk of neuropathy with long term use 
• varnostne nasvete, primerne za vse bolnike: o opis ter obravnavanje nevtropenije in trombocitopenije, vključno s stopnjo incidence v kliničnih študijah, o opis in obravnavanje trombemboličnega tveganja, vključno s stopnjo incidence v kliničnih študijah in izkušnje po začetku trženja, o uporabo pri bolnikih z jetrno in/ali ledvično okvaro, o odstranjevanje odvečnega zdravila, o lokalne, za državo značilne dogovore za predpisovanje in izdajanje zdravila Revlimid, o opis tveganja hipotiroidizma, o razlaga neznanega tveganja nevropatije pri dolgotrajni uporabi;
• National or other applicable specific arrangements for a prescription for Revlimid to be dispensed 
• državne in druge ustrezne dogovore za predpisovanje in izdajanje zdravila Revlimid;
• The need to stop Revlimid immediately upon suspicion of pregnancy 
• potrebo po takojšnji prekinitvi zdravljenja z zdravilom Revlimid pri sumu na nosečnost;
• Requirements in the event of pregnancy o Instructions to stop Revlimid immediately upon suspicion of pregnancy o Need to refer to physician specialised or experienced in dealing with teratology and its diagnosis for evaluation and advice o Local contact details for reporting of any suspected pregnancy o Pregnancy reporting form 
• zahteve v primeru nosečnosti: o navodila za takojšnjo prekinitev zdravljenja z zdravilom Revlimid pri sumu na nosečnost, o potrebo po napotitvi k zdravniku specialistu za teratologijo ali z izkušnjami v teratologiji na diagnozo, oceno in posvet, o podrobnosti za stike za poročanje kakršnegakoli suma na nosečnost, o obrazec za poročanje nosečnosti;
Direct Healthcare Professional Communication 
Neposredno obvestilo zdravstvenim delavcem
• Safety advice for women of childbearing potential o The need to avoid foetal exposure o Description of the PPP o Need for adequate contraception (even if woman has amenorrhoea) and definition of adequate contraception o Pregnancy test regime Advice on suitable tests Before commencing treatment During treatment based on method of contraception After finishing treatment o Need to stop Revlimid immediately upon suspicion of pregnancy o Need to tell treating doctor immediately upon suspicion of pregnancy 
• varnostne nasvete za ženske v rodni dobi: o potrebo po izogibanju fetalni izpostavljenosti, o opis PPN-ja, o potrebo po ustrezni kontracepciji (tudi, če ima ženska amenorejo) in opredelitev ustrezne kontracepcije, o režim testov nosečnosti: nasvete za ustrezne teste, pred začetkom zdravljenja, med zdravljenjem, glede na kontracepcijsko metodo, po končanem zdravljenju, o potrebo po takojšnji prekinitvi zdravljenja z zdravilom Revlimid pri sumu na nosečnost, o potrebo po takojšnjem obveščanju lečečega zdravnika pri sumu na nosečnost;
• Pregnancy test regime o Before commencing treatment o During treatment every 4 weeks except in case of confirmed tubal sterilisation o After finishing treatment 
o med zdravljenjem vsake 4 tedne razen v primeru sterilizacije jajcevodov,
• Obligations of the health care professional in relation to the prescribing of Revlimid o Need to provide comprehensive advice and counselling to patients o That patients should be capable of complying with the requirements for the safe use of Revlimid o Need to provide patients with appropriate patient educational brochure and patient card 
o bolniki morajo biti sposobni upoštevati zahteve za varno uporabo zdravila Revlimid, o bolnikom je treba priskrbeti ustrezno izobraževalno brošuro in kartico bolnika;
• A core text as agreed by the CHMP. 
• osrednjega besedila, ki ga odobri Odbor za uporabo zdravil v humani medicini (CHMP)
• That if his partner becomes pregnant he should inform his treating doctor immediately 
• opozorilo, da mora takoj obvestiti lečečega zdravnika, če partnerica zanosi.
• Safety advice for men o The need to avoid foetal exposure o The need to use condoms if sexual partner is pregnant or a WCBP (even if man has had a vasectomy) During Revlimid treatment For one week following final dose. 
• varnostne nasvete za moške: o potrebo po izogibanju fetalni izpostavljenosti, o potrebo po uporabi kondomov, če je spolna partnerica noseča ali ŽRD (tudi, če je moški imel vazektomijo): med zdravljenjem z zdravilom Revlimid, še en teden po zadnjem odmerku, o če partnerica zanosi, medtem ko bolnik jemlje zdravilo Revlimid ali kmalu po prenehanju jemanja zdravila Revlimid, mora takoj obvestiti lečečega zdravnika;
• Posology 
• odmerjanje;
March 2021 
Marec 2021
Some of these side effects may be serious and may lead to hospitalization. 
Nekateri od teh neželenih učinkov so lahko resni in povzročijo hospitalizacijo.
Studies in animals have not been performed. 
Študij na živalih niso izvedli.
The clinical study report should be submitted by March 2021. 
Poročilo o klinični študiji je treba predložiti do marca 2021.
What to check before infusion 
Kaj je treba preveriti pred infundiranjem
MARKETING AUTHORISATION NUMBER EU/1/16/1121/001 
ŠTEVILKA DOVOLJENJA ZA PROMET EU/1/16/1121/001
Progress updates should be submitted yearly with the annual renewal. 
Posodobitve o napredovanju je treba predložiti letno z letnimi pregledi.
This may be because of manufacturing issues. 
Razlog za so težave v izdelavi.
No specific paediatric group has been studied at present. 
Pediatrična populacija Zaenkrat specifične pediatrične skupine niso preučevali.
This will ensure that the cells can be eliminated before they can cause damage to the patient's cells. 
S tem se zagotovi, da se celice uničijo, preden poškodujejo bolnikove celice.
This medicinal product contains genetically-modified cells. 
To zdravilo vsebuje gensko spremenjene celice.
• The Certificate of Analysis is marked as rejected. 
• je analizni certifikat označen kot zavrnjen,
Currently, no data are available for these patients. 
Trenutno podatkov za te bolnike ni na voljo.
There were no GvHD-related deaths or long-term complications. 
Smrtnih primerov ali dolgotrajnih zapletov, povezanih z GvHD, ni bilo.
• You have not received the Certificate of Analysis. 
• niste prejeli analiznega certifikata,
Additional infusions are given once a month, for up to 4 months. 
Dodatne infuzije se dajejo enkrat na mesec do največ 4 mesece.
The safety and efficacy in children and adolescents (less than 18 years) have not been established. 
Varnost in učinkovitost zdravila pri otrocih in mladostnikih (mlajših od 18 let), nista bili dokazani.
However, the risk of transmitting infectious viruses to healthcare professionals cannot be totally excluded. 
Kljub temu tveganja za prenos kužnih virusov na zdravstvene delavce ni možno povsem izključiti.
Your doctor will closely supervise the treatment therapy. 
Vaš zdravnik bo zdravljenje natančno spremljal.
It is unlikely that you will be given too much. 
Ni verjetno, da bi prejeli preveč zdravila.
Chronic GvHD 
kronična GvHD
Non clinical safety data obtained in two different immunedeficient animal models for GvHD did not indicate special hazards for humans, but allowed only a very limited safety assessment. 
Predklinični podatki o varnosti, pridobljeni v dveh različnih živalskih modelih z imunsko pomanjkljivostjo za GvHD niso pokazali posebnega tveganja za človeka, vendar je bila mogoča le zelo omejena ocena varnosti.
• Put the bag into two plastic envelopes (double envelopment) to avoid direct contact with water. 
• Vrečo vstavite v dve plastični ovojnini (dvojni ovoj), da preprečite neposredni stik z vodo.
Patient code: 
Koda bolnika:
Please inform your doctor if you are taking, have recently taken or might take any other medicines. 
Obvestite zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Severity of acute GvHD was grade 1 in one case (3%), grade 2 in seven (23%), grade 3 in one (3%) and grade 4 in one (3%). 
Resnost akutne GvHD je bila v enem primeru 1. stopnje (3 %), v sedmih primerih 2. stopnje (23 %), v enem primeru 3. stopnje (3 %) in v enem primeru 4. stopnje (3 %).
The bag is put in a second bag (intermediate container) and this one is placed in an aluminium box (outer container). 
Vreča je vstavljena v drugo vrečo (vmesni vsebnik), ta pa se položi v aluminijasto škatlo (zunanji vsebnik).
This medicine is prescribed by a doctor and given in a hospital under strict survelliance and predetermined schedule so that you cannot forget your dose. 
To zdravilo predpiše zdravnik in se daje v bolnišnici pod natančnim spremljanjem in vnaprej določenem načrtu, zato na odmerek ne morete pozabiti.
However, you should pay attention to your overall status when considering performing tasks that require judgment, motor or cognitive skills. 
Vendar pa bodite pozorni na svoje splošno stanje, če želite opravljati naloge, pri katerih morate biti presodni ali uporabljati motorične in kognitivne spretnosti.
Annex IV Conclusions on the granting of the conditional marketing authorisation and similarity presented by the European Medicines Agency 
PRILOGA IV SKLEPNE UGOTOVITVE O PRIDOBITVI POGOJNEGA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER PODOBNOSTI, KI JIH JE PREDSTAVILA EVROPSKA AGENCIJA ZA ZDRAVILA
This strategy allows the direct targeting of those T lymphocytes that are initiating the GvHD response. 
Ta strategija omogoča neposredno ciljanje limfocitov T, ki sprožijo odziv GvHD.
One patient with grade 1 acute GvHD did not receive any treatment. 
En bolnik z akutno GvHD 1. stopnje ni prejel nobenega zdravljenja.
Both acute and chronic GvHD events developed only in patients who had achieved immune reconstitution. 
Tako akutni kot kronični dogodki GvHD so se razvili le pri bolnikih, ki so dosegli imunsko reaktivacijo.
Women of childbearing potential have to provide a negative pregnancy test (serum or urine) within 14 days prior to start the treatment. 
Ženske v rodni dobi morajo predložiti negativen test nosečnosti (serumski ali urinski), opravljen v roku 14 dni pred začetkom zdravljenja.
The amount of cells to be administered depends on your body weight. 
Količina celic, ki jih boste prejeli, je odvisna od vaše telesne mase.
In addition to T cells, NK cells and residual levels of monocytes and of B cells may be present. 
Poleg celic T so lahko prisotne tudi celice NK in rezidualne ravni monocitov in B-celic.
The nature and the intended use of the product are such that conventional studies on pharmacokinetics including absorption, distribution, metabolism and excretion are not applicable. 
Narava in namen uporabe zdravila je taka, da običajne študije farmakokinetike, vključno z absorpcijo, porazdelitvijo, presnovo in izločanjem, niso smiselne.
There was no significant difference regarding leukaemia free survival and the chance for relapse. 
Značilne razlike glede preživetja brez levkemije in možnosti za recidiv ni bilo.
Donors are tested for transmissible infectious agents in line with applicable local requirements. 
Darovalci so testirani za povzročitelje nalezljivih bolezni v skladu z veljavnimi lokalnimi zahtevami.
Acute GvHD (33% of patients) 
Bolezni imunskega sistema akutna GvHD (33 % bolnikov)
The whole package is secured in a liquid nitrogen container designed to maintain the appropriate transportation and storage temperature until the time of infusion. 
Celotna pošiljka se vstavi v vsebnik s tekočim dušikom, kar zagotavlja ustrezen prevoz in temperaturo shranjevanja do trenutka infundiranja.
Pharmacotherapeutic group: Other antineoplastic agents, ATC code: not yet assigned 
Farmakoterapevtska skupina: druga zdravila proti novotvorbam, oznaka ATC: še ni bila dodeljena
The hospital staff are responsible for the correct storage of the product both before and during its use, as well as for correct disposal. 
Za pravilno shranjevanje zdravila pred in med uporabo ter za pravilno odstranjevanje je odgovorno osebje v bolnišnici.
Seven patients needed to add an immunosuppressive treatment consisting of steroids, mycophenolate and/or cyclosporine. 
Sedem bolnikov je potrebovalo dodatno imunosupresivno zdravljenje, sestavljeno iz steroidov, mikofenolata in/ali ciklosporina.
Tel +39-02-212771 Fax +39-02-21277220 info@molmed.com 
20132 Milano Italija tel. (+39) -02-212771 faks +39-02-21277220 e-pošta info@molmed.com
Remarks on the importance of reporting ADRs and encourage patients to be enrolled into study TK011 (linked with the EBMT registry) 
Opombe o pomenu poročanja neželenih učinkov in spodbujanja bolnikov, da se vključijo v študijo TK011 (povezana z registrom EBMT)
Via Olgettina 58 20132 Milano Italy e-mail: info@molmed.com 
Via Olgettina 58 20132 Milano Italija e-pošta: info@molmed.com
In this case, Zalmoxis may be administered after an adequate wash out period (the time necessary to remove a medicine from your body). 
V tem primeru se lahko zdravilo Zalmoxis daje po ustreznem obdobju izpiranja (čas, potreben za odstranitev zdravila iz telesa).
Q4 2022 
4. četrtletje 2022